Loading…
Loading…
how do you think that plays out? Like could this be a challenge if you have to titrate patients and some don't get the benefit of the efficacy
at this point, are you able to pursue first-line or naive patients in registrational studies
Just if you can share what are your expectations, here in these studies in terms of, the efficacy that would be great
Can you confirm the 1Q BRINSUPRI gross to net that you mentioned? Is it at the top end of the range, the mid-20s to low 30s?
do you have this data in-house already just realizing that the primary completion was also August
just trying to get a sense of how soon can we get there at the 4% run rate
You are effectively spending $700–$850 pre-tax charges for a $400 million net savings. Is this within typical benchmark range
is that the right way to think about how you spend it out as in thre's more potential for savings from commercial, followed by R&D and then COGS
I wanted to ask about the China business. It seems particularly strong this quarter. I know you called out some purchasing patterns. What's the growth excluding that
on the enterprise-wide strategic review, still waiting to hear a little bit of clarity in terms of what is the scope of activities that you want to showcase and what's the time line for that
can you help us understand how fast acting is this? For example, how quickly does this get static benefit in terms of hours
Is there more appetite here to go up substantially on the repo given where the stock is
typically these type of warning letters can take a minimum of two years to dissolve
the stock is trading sort of mid-teens down in pre-market. Why not be even more aggressive on the buyback here